LSTA (Lisata Therapeutics) Debt-to-Asset : 0.01 (As of Sep. 2024)

View and export this data going back to 1999. Start your Free Trial

What is Lisata Therapeutics Debt-to-Asset?

Lisata Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.18 Mil. Lisata Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.00 Mil. Lisata Therapeutics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2024 was $38.20 Mil. Lisata Therapeutics's debt to asset for the quarter that ended in Sep. 2024 was 0.00.

Lisata Therapeutics Debt-to-Asset Historical Data

The historical data trend for Lisata Therapeutics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lisata Therapeutics Debt-to-Asset Chart

Lisata Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.04

0.02

0.01

Lisata Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Asset	Get a 7-Day Free Trial															-	-	-	-	0.01

Competitive Comparison of Lisata Therapeutics's Debt-to-Asset

For the Biotechnology subindustry, Lisata Therapeutics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lisata Therapeutics's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lisata Therapeutics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Lisata Therapeutics's Debt-to-Asset falls into.

Lisata Therapeutics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Lisata Therapeutics's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.168	+	0)	/	54.694
	=	0.00

Lisata Therapeutics's Debt-to-Asset for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.181	+	0)	/	38.199
	=	0.00

Lisata Therapeutics (NAS:LSTA) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Lisata Therapeutics Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Lisata Therapeutics's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Lisata Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lisata Therapeutics Inc (NAS:LSTA) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

0HS8:UK 8NE:Germany

Address

110 Allen Road, 2nd Floor, Basking Ridge, NJ, USA, 07920

Website

https://www.lisata.com

Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Its product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively.

Executives

David W. Slack	director, officer: President & CBO	110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE NJ 07920
Heidi Henson	director	2173 SALK AVENUE, SUITE 250, PMB#052, CARLSBAD CA 92008
Mohammad Azab	director	C/O SUPERGEN, INC., 4140 DUBLIN BLVD., SUITE 200, DUBLIN CA 94568
Erkki Ruoslahti	director	P.O. BOX 544, BUELLTON CA 93427
Steven S Myers	director	4695 MACAUTHUR COURT, EIGHTH FLOOR, NEWPORT BEACH CA 92660
Kristen K Buck	officer: EVP, R&D and CMO	110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE NJ 07920
Todd C Girolamo	officer: CLO, SVP of Corp Dev	110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE NJ 07920
Anne Clem Whitaker	director	109 BRIERY BRANCH COURT, MORRISVILLE NC 27560
Michael H. Davidson	director	OMTHERA PHARMACEUTICALS, INC., 707 STATE ROAD, PRINCETON NJ 08540
Cynthia Schwalm	director	C/O G1 THERAPEUTICS, 700 PARK OFFICES DR, SUITE 200, P.O. BOX 110341, RESEARCH TRIANGLE PARK NC 27709
David J Mazzo	director, officer: Chief Executive Officer	110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE NJ 07920
Joseph Talamo	officer: SVP and CFO	CALADRIUS BIOSCIENCES, INC., 800 WESTCHESTER AVENUE. STE N341, RYE BROOK NY 10573
Douglas W Losordo	officer: See Remarks	13 FOX MEADOW RD, SCARSDALE NY 10583
Anford	10 percent owner	P.O. BOX 5039, SIOUX FALLS SD 57117
Health Sanford	10 percent owner	P.O. BOX 5039, SIOUX FALLS SD 57117